Literature DB >> 31565701

Alzheimer's Pathogenesis, Metal-Mediated Redox Stress, and Potential Nanotheranostics.

Willam T Wang1, Breeya A Tailor2, David S Cohen2, Xudong Huang2.   

Abstract

Alzheimer's disease (AD) characterized by insoluble amyloid-β (Aβ) deposits, neurofibrillary tangles (NFTs), and neuronal demise. The influence of environmental and genetic factors on AD progression remains elusive, however evidence suggests biometal dyshomeostasis elicits neuronal death, neuroinflammation, and accumulated oxidative damages in AD brain. As such, three pathways have been identified that result from abnormal biometal accumulation and increased levels of reactive oxygen species (ROS) and reactive nitrogen species (RNS) in AD brain parenchyma: (1) the damage caused by direct oxidation of cellular components such as DNA and proteins; (2) the oligomerization of Aβ and NFTs, and (3) the promotion of apoptosis through NF-κB signaling pathway. Finally, given recent developments in nanotechnology, we have briefly reviewed potential nanotheranostic agents as potential AD theranostics.

Entities:  

Keywords:  Alzheimer’s Disease; Aβ Amyloid; Biometals; Blood-Brain Barrier; Metal Chelators; Nanotheranostics; Redox Stress; Tau Protein

Year:  2019        PMID: 31565701      PMCID: PMC6764777     

Source DB:  PubMed          Journal:  EC Pharmacol Toxicol


  111 in total

Review 1.  Alzheimer's disease: clinical trials and drug development.

Authors:  Francesca Mangialasche; Alina Solomon; Bengt Winblad; Patrizia Mecocci; Miia Kivipelto
Journal:  Lancet Neurol       Date:  2010-07       Impact factor: 44.182

Review 2.  Role of free radicals and catalytic metal ions in human disease: an overview.

Authors:  B Halliwell; J M Gutteridge
Journal:  Methods Enzymol       Date:  1990       Impact factor: 1.600

Review 3.  Lipids and the pathogenesis of Alzheimer's disease: is there a link?

Authors:  Michelle M Mielke; C G Lyketsos
Journal:  Int Rev Psychiatry       Date:  2006-04

4.  Oxidative regulation of fatty acid-induced tau polymerization.

Authors:  T C Gamblin; M E King; J Kuret; R W Berry; L I Binder
Journal:  Biochemistry       Date:  2000-11-21       Impact factor: 3.162

5.  2016 Alzheimer's disease facts and figures.

Authors: 
Journal:  Alzheimers Dement       Date:  2016-04       Impact factor: 21.566

6.  Copper binding to the amyloid-beta (Abeta) peptide associated with Alzheimer's disease: folding, coordination geometry, pH dependence, stoichiometry, and affinity of Abeta-(1-28): insights from a range of complementary spectroscopic techniques.

Authors:  Christopher D Syme; Rebecca C Nadal; Stephen E J Rigby; John H Viles
Journal:  J Biol Chem       Date:  2004-02-20       Impact factor: 5.157

Review 7.  Therapeutics for Alzheimer's disease based on the metal hypothesis.

Authors:  Ashley I Bush; Rudolph E Tanzi
Journal:  Neurotherapeutics       Date:  2008-07       Impact factor: 7.620

8.  Cupric-amyloid beta peptide complex stimulates oxidation of ascorbate and generation of hydroxyl radical.

Authors:  Sergey I Dikalov; Michael P Vitek; Ronald P Mason
Journal:  Free Radic Biol Med       Date:  2004-02-01       Impact factor: 7.376

9.  An iron-responsive element type II in the 5'-untranslated region of the Alzheimer's amyloid precursor protein transcript.

Authors:  Jack T Rogers; Jeffrey D Randall; Catherine M Cahill; Paul S Eder; Xudong Huang; Hiromi Gunshin; Lorene Leiter; Jay McPhee; Satinder S Sarang; Tada Utsuki; Nigel H Greig; Debomoy K Lahiri; Rudolph E Tanzi; Ashley I Bush; Tony Giordano; Steve R Gullans
Journal:  J Biol Chem       Date:  2002-08-26       Impact factor: 5.157

10.  Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial.

Authors:  S Gilman; M Koller; R S Black; L Jenkins; S G Griffith; N C Fox; L Eisner; L Kirby; M Boada Rovira; F Forette; J-M Orgogozo
Journal:  Neurology       Date:  2005-05-10       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.